Inflammatory bowel disease (IBD) and Symprove study overview

In this double-blind, placebo-controlled trial 80 adults aged between 18 and 65-years-old with ulcerative colitis (who were all in remission at the time of the study starting) were randomised to receive either Symprove or a matching placebo drink for one month.

Faecal calprotectin levels were measured before and after treatment. Reductions in calprotectin levels (intestinal inflammation) were observed in the majority (76%) of patients with ulcerative colitis. The decrease in intestinal inflammation was significantly greater than in the placebo group.

The study was carried out by Dr Guy Sisson, Dr Bu Hayee and Professor Ingvar Bjarnason of Darent Valley Hospital and King’s College London.

Assessment of a multi-strain probiotic (Symprove®) in IBD: A randomised, double-blind, placebo-controlled trial
Assessment of a multi-strain probiotic (Symprove®) in IBD: A randomised, double-blind, placebo-controlled trial
Assessment of a multi-strain probiotic (Symprove®) in IBD: A randomised, double-blind, placebo-controlled trial
Assessment of a multi-strain probiotic (Symprove®) in IBD: A randomised, double-blind, placebo-controlled trial

76% of patients with ulcerative colitis saw significant reductions in faecal calprotectin levels

This is an interesting result showing that Symprove reduces intestinal inflammation in this group of patients, without any observed side effects. There is now a need to see if these reductions in intestinal inflammation are maintained with long-term ingestion and whether this reduces the incidence of symptom flare-ups.

Professor Ingvar Bjarnason, consultant gastroenterologist and principal investigator of the study

The results were published in the leading world Gastroenterology congress, Digestive Disease Week, in Washington USA in 2015, and the abstract was published in Gastroenterology Journal in 2015. Full publication is in progress.